NuLens selected as a 2008 Technology Pioneer

Article

The World Economic Forum has selected 39 companies as Technology Pioneers for 2008 and NuLens is one of those honoured with this title.

The World Economic Forum has selected 39 companies as Technology Pioneers for 2008 and NuLens is one of those honoured with this title.

The Technology Pioneers were nominated by the world's leading technology experts, including venture capitalists, technology companies, academics and the media. The final selection from 273 nominees was made by a panel appointed by the World Economic Forum. Those selected are invited to participate in the World Economic annual meeting 2008 and in the Annual Meeting of the New Champions.

NuLens is currently developing a new accommodative intraocular lens (IOL) that is designed to enhance a patient's quality of vision following cataract surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.